Editorial: Megakaryocytes as regulators of tumor microenvironments.
作者信息
Migliaccio Anna Rita, Balduini Alessandra, Zhan Huichun
机构信息
Center for Integrated Biomedical Research, Campus Bio-medico, Rome, Italy.
Altius Institute for Biomedical Sciences, Seattle, WA, United States.
出版信息
Front Oncol. 2022 Nov 25;12:1090658. doi: 10.3389/fonc.2022.1090658. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Megakaryocytes as regulators of tumor microenvironments.
Front Oncol. 2022 Nov 25;12:1090658. doi: 10.3389/fonc.2022.1090658. eCollection 2022.
2
Resident Self-Tissue of Proinflammatory Cytokines Rather Than Their Systemic Levels Correlates with Development of Myelofibrosis in Mice.
Biomolecules. 2022 Jan 30;12(2):234. doi: 10.3390/biom12020234.
3
Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.
Front Oncol. 2022 May 11;12:906698. doi: 10.3389/fonc.2022.906698. eCollection 2022.
4
PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients.
J Pathol Clin Res. 2022 Jan;8(1):78-87. doi: 10.1002/cjp2.240. Epub 2021 Sep 4.
5
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial.
Clin Cancer Res. 2019 Aug 15;25(16):4898-4906. doi: 10.1158/1078-0432.CCR-19-1005. Epub 2019 May 6.
6
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
7
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
Haematologica. 2015 Jun;100(6):757-67. doi: 10.3324/haematol.2014.118497. Epub 2015 Apr 3.
8
Megakaryocytes in cubital venous blood in patients with chronic myeloproliferative diseases.
Scand J Haematol. 1983 Jan;30(1):50-8. doi: 10.1111/j.1600-0609.1983.tb00634.x.
9
Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis.
Front Oncol. 2020 Nov 16;10:584541. doi: 10.3389/fonc.2020.584541. eCollection 2020.
10
The Role of Megakaryocytes in Myelofibrosis.
Hematol Oncol Clin North Am. 2021 Apr;35(2):191-203. doi: 10.1016/j.hoc.2020.11.004. Epub 2021 Jan 11.
引用本文的文献
1
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.
Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323.
本文引用的文献
1
CXCR4 megakaryocytes regulate host-defense immunity against bacterial pathogens.
Elife. 2022 Jul 29;11:e78662. doi: 10.7554/eLife.78662.
2
Myeloproliferative disorders and their effects on bone homeostasis: the role of megakaryocytes.
Blood. 2022 May 26;139(21):3127-3137. doi: 10.1182/blood.2021011480.
3
Single-cell analysis of ploidy and the transcriptome reveals functional and spatial divergency in murine megakaryopoiesis.
Blood. 2021 Oct 7;138(14):1211-1224. doi: 10.1182/blood.2021010697.
4
Lung megakaryocytes display distinct transcriptional and phenotypic properties.
Blood Adv. 2020 Dec 22;4(24):6204-6217. doi: 10.1182/bloodadvances.2020002843.
5
Decoding Human Megakaryocyte Development.
Cell Stem Cell. 2021 Mar 4;28(3):535-549.e8. doi: 10.1016/j.stem.2020.11.006. Epub 2020 Dec 18.
6
Lung megakaryocytes are immune modulatory cells.
J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI137377.
7
CCL2/CCR2 signaling in cancer pathogenesis.
Cell Commun Signal. 2020 May 29;18(1):82. doi: 10.1186/s12964-020-00589-8.
8
Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia.
Cancer Cell. 2020 Jun 8;37(6):867-882.e12. doi: 10.1016/j.ccell.2020.04.015. Epub 2020 May 28.
9
Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.
F1000Res. 2019 Sep 19;8. doi: 10.12688/f1000research.18581.1. eCollection 2019.
10
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.
Zotero 插件